Vivo Capital

Chentai New Materials integrates the R&D, design, manufacturing, and sales of high-performance composite ceramics. It Specializes in the innovation and creation of medical high-performance ceramic products.

Cidara Therapeutics is a biotechnology company based in San Diego, California, established in 2012. The company specializes in the discovery and development of innovative anti-infective therapies for serious diseases, particularly those that affect individuals with compromised immune systems. Its lead candidate, rezafungin acetate, is an antifungal agent designed to treat and prevent severe invasive fungal infections, such as candidemia and invasive candidiasis, which carry significant mortality risks. In addition to its antifungal efforts, Cidara is advancing its proprietary Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating various viral infections, including influenza, RSV, HIV, and coronavirus. Cidara's mission is to transform treatment and prevention strategies for life-threatening illnesses.

Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.

Serán is a contract development and manufacturing organization providing a comprehensive suite of development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies.

Tenax Therapeutics, Inc. is a specialty pharmaceutical company dedicated to the identification, development, and commercialization of products aimed at addressing cardiovascular and pulmonary diseases with significant unmet medical needs. Headquartered in Morrisville, North Carolina, Tenax focuses on levosimendan, a pharmaceutical product designed to reduce morbidity and mortality in cardiac surgery patients at risk for low cardiac output syndrome. The company is also actively conducting a Phase 2 clinical trial to explore the efficacy of levosimendan in treating pulmonary hypertension associated with heart failure with preserved ejection fraction. Additionally, Tenax is involved in developing novel formulations of imatinib mesylate, a kinase inhibitor with the potential to serve as a disease-modifying therapy for pulmonary arterial hypertension. Founded in 1967, Tenax Therapeutics underscores its commitment to advancing treatments within these critical therapeutic areas.

Ajax Therapeutics is a biotechnology company based in New York City that focuses on developing innovative small molecule therapies for hematologic malignancies. The company utilizes computational chemistry and structure-based technologies to create targeted treatments that address critical cytokine signaling pathways involved in these diseases. By integrating insights from disease mechanisms, genetics, and structural biology with an advanced computational drug discovery platform, Ajax Therapeutics aims to design precise therapeutics that meet significant unmet medical needs for patients suffering from hematologic malignancies.

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA.

Abeona Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing gene and cell therapies for severe, life-threatening rare genetic diseases. The company's leading programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, and ABO-102 and ABO-101, which are AAV-based gene therapies targeting Sanfilippo syndrome types A and B, respectively. Additional therapies under development include ABO-201 and ABO-202 for Batten disease, ABO-401 for cystic fibrosis, and ABO-5OX for genetic eye disorders. Abeona also operates the AIM Vector Platform, which focuses on advancing gene therapy delivery methods using next-generation AAV capsids. The company is engaged in a licensing agreement with REGENXBIO for gene therapies addressing multiple genetic disorders. Founded in 1974 and headquartered in New York, Abeona has a fully operational manufacturing facility that supports its preclinical and clinical research efforts.

Clasp Therapeutics is focused on advancing cancer treatment through its innovative immunotherapeutics platform. The company develops precision medicines designed to enhance the immune system's ability to identify and eliminate challenging tumors that possess common driver mutations, irrespective of the tumor type. By enabling the targeting of cancer-specific markers, Clasp Therapeutics aims to allow for precise and selective destruction of tumor cells, thereby improving therapeutic outcomes in the field of immuno-oncology.

Geron Corporation is a late-stage clinical biopharmaceutical company headquartered in Menlo Park, California, that specializes in developing therapies for hematologic myeloid malignancies. The company's lead product, imetelstat, is a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. This investigational drug aims to inhibit the uncontrolled proliferation of malignant progenitor cells, which can lead to dysfunctional blood cell production, thereby facilitating the recovery of normal blood cell development. Founded in 1990, Geron focuses on advancing treatments for conditions such as myelodysplastic syndromes and myelofibrosis, a rare blood cancer affecting bone marrow. The company also generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements.

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s Syndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease. Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.

Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company based in San Diego, California, specializing in the discovery and development of therapies that target microRNAs for various diseases. The company is advancing its lead product candidates, RG-012 and RGLS4326, which are in Phase II and Phase Ib clinical trials, respectively. RG-012 targets miR-21 for the treatment of Alport syndrome, a severe kidney disease, while RGLS4326 targets miR-17 for autosomal dominant polycystic kidney disease. In addition to these candidates, Regulus is developing a pipeline of preclinical drug products, including RGLS5579, aimed at inhibiting miR-10b, as well as programs targeting hepatitis B virus and non-alcoholic steatohepatitis. Founded in 2007, Regulus Therapeutics is at the forefront of leveraging the therapeutic potential of microRNA, a significant scientific breakthrough in recent years.

Attralus, Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from systemic amyloidosis. The company develops innovative peptide-based agents aimed at diagnosing and treating various forms and stages of this complex condition. Its product pipeline includes AT-01, a polybasic peptide radiotracer for diagnostic and monitoring purposes; AT-02, a peptide-immunoglobulin fusion for therapeutic applications; and AT-03, an Fc-fusion protein designed for therapeutic use. Attralus focuses on addressing the common pathology found in all systemic amyloidosis diseases, striving to create effective treatments for subtypes that currently lack available options. Founded in 2010 and headquartered in South San Francisco, California, Attralus was previously known as Aurora Bio, Inc. before rebranding in August 2020.

Adverum Biotechnologies is a clinical-stage gene therapy company focused on developing innovative treatments for ocular and rare diseases. The company's pipeline includes several product candidates, notably ADVM-022, which targets wet age-related macular degeneration through a single intravitreal injection designed to deliver long-lasting therapeutic effects. Other candidates include ADVM-043 for alpha-1 antitrypsin deficiency and ADVM-053 for hereditary angioedema. Adverum collaborates with Editas Medicine to utilize its proprietary AAV vectors for gene editing in inherited retinal diseases, and with Regeneron Pharmaceuticals for developing various ocular therapies. Founded in 2006 and headquartered in Redwood City, California, Adverum aims to establish gene therapy as a new standard of care, aspiring to restore vision and prevent blindness in affected patients.

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

Tourmaline Bio is a late-stage clinical biotechnology company focused on developing transformative medicines aimed at improving the lives of patients with immune diseases. Its primary product candidate, TOUR006, is a fully human monoclonal antibody that targets interleukin-6 (IL-6), a significant proinflammatory cytokine implicated in various autoimmune and inflammatory disorders. The company leverages over twenty years of clinical and commercial experience associated with the anti-IL-6 and anti-IL-6 receptor antibody class, which has effectively treated over a million patients suffering from a range of autoimmune conditions. Tourmaline Bio is committed to addressing the needs of individuals with life-altering immune diseases through its innovative therapeutic approaches.

Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.

Ronovo Surgical is an emerging medical technology company dedicated to innovating minimally invasive and digital surgery. The company has developed a soft tissue surgery robot platform that utilizes advanced robotics and digital solutions to enhance surgical procedures. This platform aims to improve efficiency and precision across various surgical specialties, ultimately optimizing patient outcomes and health economics. By focusing on these innovations, Ronovo Surgical seeks to disrupt traditional surgical care in China and address the evolving needs of the medical industry.

COMPASS Pathways plc is a mental health care company based in the United Kingdom and the United States, focusing on developing innovative therapies for treatment-resistant depression. The company is conducting Phase IIb clinical trials for its psilocybin formulation, COMP360, which aims to provide a new treatment option for patients who have not responded to conventional therapies. By researching psilocybin-assisted therapy, COMPASS Pathways seeks to assess its safety and efficacy, while combining the psychedelic compound with psychological support. The company was incorporated in 2020 and aims to address the significant unmet need for effective and accessible mental health treatments, striving to empower individuals facing mental health challenges.

ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing cell therapies for cancer treatment. The company’s lead product candidates include GC012F, a dual-target autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia and is also being investigated for relapsed or refractory B cell non-Hodgkin’s lymphoma. Additionally, Gracell is developing GC007F for B cell non-Hodgkin's lymphoma and GC027, an allogeneic CAR-T product candidate for adult T cell acute lymphoblastic leukemia. The company also has GC007g, a donor-derived therapy for relapsed or refractory B cell acute lymphoblastic leukemia, and a pipeline of earlier stage candidates targeting other cancer types, including ovarian cancer and breast cancer. Founded in 2017, Gracell aims to provide innovative cellular therapeutics that enhance treatment options for patients suffering from various hematological malignancies and solid tumors.

Ossium Health, Inc. is engaged in the development and manufacturing of cell therapy products aimed at treating leukemia, other blood cancers, and tissue damage, as well as addressing radiation poisoning. The company offers a range of innovative therapies, including HPC, Marrow, which features HLA-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients; Chimera, which enhances organ transplantation; and Chymalis, composed of mesenchymal stem cells that promote the healing of damaged bone and muscle tissue. Additionally, Ossium provides bone marrow cells for research purposes in oncology and immunology. Founded in 2016 and headquartered in San Francisco, California, Ossium Health focuses on improving health outcomes and longevity through advanced bioengineering techniques.

EpiBiologics focuses on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. The company utilizes its EpiTAC platform to create therapeutics that degrade these disease-driving proteins, addressing the underlying biology of disorders. By specializing in protein degradation, EpiBiologics enables researchers to manipulate cellular proteostasis, offering potential solutions for a wide range of medical conditions.

Delcath Systems, Inc. is an interventional oncology company based in New York that specializes in the treatment of primary and metastatic liver cancers. The company's primary product is Melphalan Hydrochloride for Injection, which is used in conjunction with the Delcath Hepatic Delivery System to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure and side effects. Delcath is currently conducting Phase III clinical trials, including the FOCUS Trial for patients with hepatic dominant ocular melanoma and the ALIGN Trial for intrahepatic cholangiocarcinoma. Additionally, Delcath offers Melphalan Hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System in Europe. Founded in 1988, Delcath Systems is dedicated to advancing treatment options for patients with liver cancer.

EpiBiologics focuses on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. The company utilizes its EpiTAC platform to create therapeutics that degrade these disease-driving proteins, addressing the underlying biology of disorders. By specializing in protein degradation, EpiBiologics enables researchers to manipulate cellular proteostasis, offering potential solutions for a wide range of medical conditions.

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s Syndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease. Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.

Ronovo Surgical is an emerging medical technology company dedicated to innovating minimally invasive and digital surgery. The company has developed a soft tissue surgery robot platform that utilizes advanced robotics and digital solutions to enhance surgical procedures. This platform aims to improve efficiency and precision across various surgical specialties, ultimately optimizing patient outcomes and health economics. By focusing on these innovations, Ronovo Surgical seeks to disrupt traditional surgical care in China and address the evolving needs of the medical industry.

Rgenta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA-targeting medicines with a primary focus on oncology and neurological disorders. Founded in 2018, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This platform enables the design of small-molecule compounds that modulate interactions among the spliceosome, regulatory proteins, and RNAs. By unlocking the therapeutic potential of previously undruggable targets, Rgenta aims to create oral, small-molecule therapies that address critical needs in human disease treatment, particularly in the realm of cancer.

Bonum Therapeutics is a biopharmaceutical company focused on developing innovative protein-based drugs designed to treat various diseases, with a primary emphasis on cancer. The company has established a technology platform that enables the creation of drugs with regulated, context-dependent activity. These drugs are engineered to sense their local environment and transition from an inactive to an active form, allowing for targeted therapeutic effects. In addition to cancer, Bonum Therapeutics also aims to address metabolic diseases, immunological conditions, and pain management, thereby expanding its potential impact across multiple therapeutic areas.

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients. The company is headquartered in Florida, USA.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing specific and selective antibody-based therapeutics for various cancers. The company employs a proprietary platform to create conditionally active biologics (CABs), which enhance targeting of cancerous tissues while minimizing effects on normal cells, thereby improving safety and efficacy. BioAtla's lead product candidate, BA3011, is a conditionally active biologic designed to treat soft tissue and bone sarcomas, non-small cell lung cancer, and other tumors. The company is also advancing BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, aimed at multiple cancer types including renal cell carcinoma and hepatocellular carcinoma. With over 150 patents and applications, BioAtla's innovative approach expands the potential for treating previously untreatable cancers and enhances the manufacturability of its drug candidates.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic antibodies for solid tumors and hematological malignancies. Founded in 2014 and based in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to identify and develop innovative antibody therapeutics. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase I clinical trials. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, and has completed a Phase 1 dose escalation study. Additionally, CTX-8371, another bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Compass Therapeutics aims to engage the immune system effectively to advance its therapeutic offerings.

Neocis, Inc. is a Miami-based company that specializes in robotic guidance systems for dental implant procedures. Founded in 2009, Neocis develops the Yomi system, a robotic device designed to enhance the precision of dental surgeries. Yomi integrates computer imagery from CT scans with surgical planning, providing dental surgeons with multi-sensory feedback during procedures. This technology aims to transform dental surgery by offering a minimally invasive approach, which can lead to faster recovery times for patients. The Yomi system has received clearance from the U.S. Food and Drug Administration and is commercially available in the United States, underscoring Neocis's commitment to advancing patient care and addressing the challenges faced by dental professionals.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in developing innovative treatments for severe rare diseases with significant unmet medical needs. Its primary product candidate, Apraglutide, is a long-acting synthetic analog of glucagon-like peptide-2 (GLP-2) designed to enhance the intestine's ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support. VectivBio aims to deliver transformational therapies that significantly improve the lives of patients and their families, rather than offering only incremental benefits over existing treatments.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases. The company has a pipeline that includes three small molecule products. Its lead program, IMU-838, is a selective immune modulator that works by inhibiting the enzyme DHODH, targeting conditions such as multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. The second product, IMU-935, functions as an inverse agonist of the transcription factor RORγt and is being developed for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Lastly, IMU-856 aims to restore intestinal barrier function and is intended for diseases associated with bowel barrier dysfunction. Through these innovative therapies, Immunic Therapeutics aims to address significant unmet medical needs in the field of immunology.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company focuses on developing antibody-based therapeutics aimed at treating various conditions linked to dysregulation of the T-helper type 2 immune response, such as allergic diseases and chronic inflammation. Its lead product, antolimab (AK002), targets conditions including eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is developing AK006, an antibody that targets Siglec-6, an inhibitory receptor found on mast cells. By binding to Siglec-6, AK006 is designed to enhance the receptor's natural inhibitory function, thereby reducing mast cell activation and associated inflammatory responses.

Klavi is a developer of an open finance platform that focuses on data aggregation, analytics, and API services. Founded in 2020 by Bruno Chan and Stone Zheng, the company provides a suite of financial management solutions, including bank account management, credit card management, and payment management. Its platform enables customers to automate the tracking and checking of accounts, credit cards, and accounts payable, thereby facilitating easier access to financial data and streamlining financial processes. Through its offerings, Klavi aims to contribute to the democratization of big data access in the financial sector.

Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. The company utilizes a microRNA-based target discovery platform to identify novel RNA dysregulated cancer drivers, which can be addressed by small molecules and biologics. Inspirna's clinical programs include first-in-class oral small molecules aimed at treating patients with RAS mutant colorectal cancer (RGX-202) and small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (RGX-104), both currently in Phase 1b/2 trials. Through its research, Inspirna aims to provide effective treatment options that specifically target cancer metabolism and progression, offering potential advancements in cancer care.

Tebra provide independent healthcare practices with digital tools and support to thrive in a new era of healthcare. Tebra is to unlock better healthcare for every patient by getting your independent practice the right technology and support to thrive. In an industry marked by broken, disparate parts, and overstuffed with processes, we are developing a single system that can truly be the backbone of practice success.

Cerebral Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Aurora, Colorado, focused on developing implanted drug-device combination therapies for neurologic diseases, particularly refractory epilepsy. The company utilizes a refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of its formulation of the anti-epileptic drug valproic acid, known as CT-010. This innovative approach aims to bypass the blood-brain barrier, enhancing treatment outcomes for patients with chronic neurological conditions. Founded in 2010, Cerebral Therapeutics is dedicated to improving the lives of individuals affected by uncontrolled neurological diseases.

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.

Scientech Medical engages in the research, development, and manufacturing of interventional medical devices.

Arrowhead and Vivo formed Visirna Therapeutics as a joint venture to bring four of the biotech's RNAi therapies to China. Through a licensing agreement, the company will focus on four of Arrowhead's therapies for cardiometabolic diseases.

Ocelot Bio brings new treatment options to patients with severe liver disease. It researches and discovers medicines that help in the treatment of hepatorenal syndrome, a complication of severe liver disease.

OMNI is an innovative pharmaceutical company focusing on the development of drug delivery technology. OMNI provides inhalation dosage forms, including inhalation aerosol, inhalation powder aerosol, inhalation nebulized solution, and nasal spray, and a design platform for supporting respiratory devices for asthma and chronic obstructive pulmonary disease.

Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.

Ablaze Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted radiotherapy (TRT) treatments for cancer patients. The company aims to introduce innovative TRT products to the Chinese market, leveraging the founders' extensive experience and networks in cross-border product development and deal-making. By focusing on advanced therapeutic solutions, Ablaze Pharmaceuticals seeks to improve the outcomes and quality of life for cancer patients in China.

HistoWiz, Inc. is a histology service company based in Brooklyn, New York, that specializes in processing, embedding, cutting, and staining mouse tissue specimens for cancer researchers in academia and the pharmaceutical industry. Founded in 2012, HistoWiz operates a fully automated histology laboratory and has developed an innovative online pathologist network. The company digitizes tissue samples and stores them in PathologyMap, its cloud database, which serves as a valuable resource for researchers. This platform not only facilitates rapid information exchange among medical scientists and research pathologists but also enhances data management and supports the integration of technology in pathology. By automating histopathology processes, HistoWiz aims to accelerate research and contribute to the discovery of new treatments for cancer.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly ABI-009, aimed at treating patients with alterations in the TSC1 or TSC2 genes, where existing mTOR inhibitors have limitations in pharmacology, drug delivery, or safety. Aadi's primary focus is on providing transformational therapies for patients with ultra-rare cancers, such as perivascular epithelioid cell tumors (PEComa). Since its founding in 2011, Aadi Bioscience has aimed to address significant unmet medical needs in oncology and related therapeutic areas.

Inbrace is a medical device company focused on innovative orthodontic solutions. Its flagship product, INBRACE, is a discreet alignment system that is placed behind the teeth, utilizing patented self-guiding technology to apply continuous forces for gentle correction of dental alignment. This approach significantly reduces pain and minimizes the number of required visits to the orthodontist, addressing common patient concerns and enhancing satisfaction. INBRACE is FDA registered and aims to expand access to orthodontic treatment, thereby driving practice growth for dental professionals. The company's platform incorporates digital treatment planning, computer modeling, and direct digital manufacturing, allowing for customized solutions that maintain high standards of care across various orthodontic cases.

Neurogastrx, Inc. is a venture-stage biopharmaceutical company developing products for the treatment of gastrointestinal disorders.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Scientia Vascular, LLC is a medical device company based in Salt Lake City, Utah, founded in 2008. It specializes in the development, manufacture, and marketing of endovascular medical devices aimed at neuro, peripheral, and coronary vascular access applications. The company's flagship product, PLATO, is a micro-catheter designed for the treatment of hemorrhagic and ischemic strokes. By utilizing advanced micromachining and microfabrication processes, Scientia Vascular creates innovative devices that enhance performance for interventional specialists. The company is committed to improving patient outcomes by providing high-precision, minimally invasive solutions tailored to the evolving needs of healthcare providers.

Esco Lifesciences Group provides enabling technologies, products, and services for the life sciences and healthcare industries, supporting academic research and scientific discoveries, clinical practice, as well as biopharmaceutical R&D and manufacturing.

Rgenta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA-targeting medicines with a primary focus on oncology and neurological disorders. Founded in 2018, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This platform enables the design of small-molecule compounds that modulate interactions among the spliceosome, regulatory proteins, and RNAs. By unlocking the therapeutic potential of previously undruggable targets, Rgenta aims to create oral, small-molecule therapies that address critical needs in human disease treatment, particularly in the realm of cancer.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company based in Bala Cynwyd, Pennsylvania, dedicated to developing treatments for complex rare diseases. Its primary focus is on Friedreich's ataxia, a rare and progressive genetic disorder, for which it is advancing its lead compound, CTI-1601, through a Phase 1 clinical program. CTI-1601 is designed as a recombinant fusion protein that delivers human frataxin, an essential protein, directly to the mitochondria using a novel cell-penetrating peptide technology. In addition to Friedreich's ataxia, Larimar aims to leverage its intracellular delivery platform to create additional fusion proteins targeting other rare diseases associated with deficiencies in bioactive compounds.

Aerobiotix is a privately held company focused on developing and manufacturing proprietary environmental management devices. Its products are designed for use in institutional healthcare, home health, and commercial settings. The company provides a range of innovative technologies that effectively eliminate airborne viruses, bacteria, and spores, thereby enhancing indoor air quality and optimizing the overall environment.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on developing diagnostic tests that assess a woman's individual risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy-related complications. Founded in 2008, Sera aims to improve maternal and neonatal health while addressing the significant economic and healthcare burdens associated with premature birth. The company's proprietary proteomics and bioinformatics platform underpins its pipeline of innovative diagnostic tests, including the PreTRM® Test, which provides physicians with critical information to identify women at higher risk for spontaneous premature delivery. By enabling earlier proactive interventions, Sera seeks to enhance pregnancy care and reduce healthcare delivery costs.

Ronovo Surgical is an emerging medical technology company dedicated to innovating minimally invasive and digital surgery. The company has developed a soft tissue surgery robot platform that utilizes advanced robotics and digital solutions to enhance surgical procedures. This platform aims to improve efficiency and precision across various surgical specialties, ultimately optimizing patient outcomes and health economics. By focusing on these innovations, Ronovo Surgical seeks to disrupt traditional surgical care in China and address the evolving needs of the medical industry.

Lepu Bio they have developed an oncology-focused pipeline of drug candidates, including ADCs, oncolytic virus drugs, and immunotherapies at clinical and pre-clinical stages.

Immune-Onc Therapeutics is a newly established bio-pharmaceutical company that focuses on developing innovative therapeutic antibodies for cancer treatment. The company applies the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology, dedicated to developing innovative antibody-drug conjugate therapies targeting CD46. The company focuses on treating late-stage multiple myeloma and prostate cancer, among other indications. Its platform is designed to advance therapies for both adenocarcinoma and neuroendocrine cancers, providing healthcare professionals with effective treatment options for patients facing these advanced stages of cancer.

Ossium Health, Inc. is engaged in the development and manufacturing of cell therapy products aimed at treating leukemia, other blood cancers, and tissue damage, as well as addressing radiation poisoning. The company offers a range of innovative therapies, including HPC, Marrow, which features HLA-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients; Chimera, which enhances organ transplantation; and Chymalis, composed of mesenchymal stem cells that promote the healing of damaged bone and muscle tissue. Additionally, Ossium provides bone marrow cells for research purposes in oncology and immunology. Founded in 2016 and headquartered in San Francisco, California, Ossium Health focuses on improving health outcomes and longevity through advanced bioengineering techniques.

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, that specializes in developing selective inhibitors of TYK2 for autoimmune diseases. Founded in 2018, the company focuses on creating innovative therapies for patients suffering from inflammatory diseases and autoimmune disorders. Its pipeline includes VTX958, an oral allosteric TYK2 inhibitor currently in Phase 1 trials, aimed at treating a variety of autoimmune conditions while minimizing the toxicities associated with broader Janus kinase inhibition. Additionally, Ventyx is advancing VTX002, a Phase 2-ready S1P1 receptor modulator for ulcerative colitis, and VTX2735, a Phase 1 peripheral inhibitor of the NLRP3 inflammasome, which is implicated in several inflammatory conditions. Through these efforts, Ventyx aims to provide effective treatment options for millions of patients.

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that features a proprietary dry-powder formulation of dihydroergotamine mesylate. This product is designed for self-administration through a pre-filled, single-use nasal delivery device and is currently undergoing Phase III clinical trials. Founded in 2016 and based in South San Francisco, California, Satsuma aims to provide an effective therapeutic option for individuals suffering from acute migraine episodes.

ASLAN Pharmaceuticals Limited is a clinical-stage biopharmaceutical company based in Singapore, focusing on developing innovative treatments in the fields of immunology and oncology. Founded in 2010, the company is dedicated to transforming the lives of patients through its clinical portfolio, which includes ASLAN004, a monoclonal therapy aimed at treating atopic dermatitis and other immunological conditions, as well as a small molecule inhibitor directed at oncology applications. ASLAN collaborates with several partners, enhancing its research and development efforts.

InnoCare is a biopharmaceutical company based in China, focused on discovering, developing, and commercializing innovative treatments for cancer and autoimmune diseases. The company boasts a skilled scientific team with extensive experience in drug innovation from both the U.S. and China, supported by an accomplished Scientific Advisory Board comprised of experts from prominent universities, hospitals, and the pharmaceutical sector. InnoCare's product pipeline includes several key therapies, such as orelabrutinib, ibrutinib, zanubrutinib, and tafasitamab, targeting hematological tumors, solid tumors, and autoimmune disorders. The company is also dedicated to addressing autoimmune diseases linked to abnormal B-cell or T-cell functions, positioning itself as a leader in advancing medical treatments and tackling complex health challenges.

Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for degenerative disorders linked to nucleotide repeat expansions. Founded in 2017 and headquartered in Solana Beach, California, the company is advancing its lead program aimed at treating Friedreich’s ataxia. Additionally, Design Therapeutics is exploring treatments for other conditions such as Fragile X syndrome and myotonic dystrophy, utilizing its proprietary GeneTACTM technology, which involves small-molecule gene-targeted therapeutics designed to modify the underlying causes of these inherited diseases. The company is committed to addressing serious monogenic disorders driven by nucleotide repeat mutations through its ongoing research and development efforts.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its proprietary T-win technology platform, the company creates immune-modulating cancer vaccines that activate T cells specifically targeting immune-suppressive molecules. This approach aims to induce the immune system to disrupt multiple pathways responsible for tumor-induced immunosuppression. IO Biotech has a solid track record in advancing both preclinical and clinical compounds, with its two lead candidates targeting IDO and PD-L1 currently in clinical development, while several additional therapies remain in the preclinical stage.

Serán is a contract development and manufacturing organization providing a comprehensive suite of development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies.

Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. It specializes in developing complement-targeted therapies aimed at treating immune-mediated diseases. The company focuses on pioneering drug discovery related to the complement system, with the goal of providing transformative therapies for individuals suffering from complement-mediated conditions.

Serán is a contract development and manufacturing organization providing a comprehensive suite of development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies.

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns is dedicated to advancing a pipeline of innovative therapeutic candidates. Its notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, an amine oxidase inhibitor. The company leverages its expertise in disease biology and medicinal chemistry, along with a capital-efficient drug discovery model and robust clinical development capabilities, to address significant unmet medical needs in both China and the global market.

Provivi Inc. specializes in developing biopesticides aimed at pest management in agriculture, commercial sectors, households, and public health. The company's innovative approach focuses on using insect pheromones, which provide a safe, environmentally friendly alternative to traditional pesticides. By leveraging biocatalysis technology initially developed at the California Institute of Technology, Provivi enhances the synthesis of these biopesticides, ensuring they are effective and free from toxic residues. Founded in 2013 and based in Santa Monica, California, the company collaborates with distributors worldwide to deliver its products, which are designed to protect food supplies sustainably and affordably. With a team of experienced professionals from biotechnology and the agricultural chemicals industry, Provivi is positioned to transform pest management practices through its advanced biological processes.

dMed is a full-service Clinical Contract Research Organization that provides industry solutions to pharma and medical device companies. Its business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance, and information solutions. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.

Elevation Oncology, Inc. is a biotechnology company dedicated to developing precision medicines for patients with genomically defined cancers. The company focuses on creating targeted therapeutics that inhibit specific genetic alterations known to drive cancer progression. Its lead drug candidate, seribantumab, targets neuregulin-1 (NRG1) fusions, which are rare genomic alterations that can be treated through targeted HER3 inhibition. Currently, seribantumab is undergoing clinical testing in the Phase 2 CRESTONE study, which evaluates its efficacy in patients with solid tumors of any origin that harbor NRG1 fusions. Founded in 2019 and based in New York, Elevation Oncology aims to make genomic tests actionable by selectively developing drugs that address these specific alterations in cancer patients.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering and developing cell therapies for cancer treatment. The company’s lead product candidates include GC012F, a dual-target autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia and is also being investigated for relapsed or refractory B cell non-Hodgkin’s lymphoma. Additionally, Gracell is developing GC007F for B cell non-Hodgkin's lymphoma and GC027, an allogeneic CAR-T product candidate for adult T cell acute lymphoblastic leukemia. The company also has GC007g, a donor-derived therapy for relapsed or refractory B cell acute lymphoblastic leukemia, and a pipeline of earlier stage candidates targeting other cancer types, including ovarian cancer and breast cancer. Founded in 2017, Gracell aims to provide innovative cellular therapeutics that enhance treatment options for patients suffering from various hematological malignancies and solid tumors.

Neocis, Inc. is a Miami-based company that specializes in robotic guidance systems for dental implant procedures. Founded in 2009, Neocis develops the Yomi system, a robotic device designed to enhance the precision of dental surgeries. Yomi integrates computer imagery from CT scans with surgical planning, providing dental surgeons with multi-sensory feedback during procedures. This technology aims to transform dental surgery by offering a minimally invasive approach, which can lead to faster recovery times for patients. The Yomi system has received clearance from the U.S. Food and Drug Administration and is commercially available in the United States, underscoring Neocis's commitment to advancing patient care and addressing the challenges faced by dental professionals.

Olema Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for estrogen receptor (ER) positive breast cancer. The company specializes in the discovery and commercialization of targeted treatments aimed at improving outcomes for women with cancer. Olema utilizes its extensive knowledge of endocrine-driven cancers and the molecular mechanisms of the ER to create drug candidates that are designed to outperform existing therapies. Currently, the company's product pipeline includes OP-1250 and OP-3136, both of which have completed discovery and preclinical studies. Olema's mission is to transform the standard of care for both pre- and post-menopausal women by providing more effective and convenient treatment options.

PatientPop, Inc. operates a comprehensive practice growth platform aimed at assisting healthcare providers in enhancing their operations and patient interactions. Founded in 2014 and based in Santa Monica, California, the company offers a range of services that include website development, search engine optimization, online advertising, scheduling, appointment reminders, reputation management, and patient satisfaction surveys. By automating various stages of the patient journey—from initial online engagement to post-appointment follow-up—PatientPop enables medical practices to attract more patients, manage their online reputation, and streamline front office operations. The platform is designed to provide healthcare providers with the tools necessary to focus on patient care while effectively growing their practices.

ESSA Pharma Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, specializing in the development of innovative therapies for prostate cancer. Founded in 2009, the company is currently focusing on EPI-7386, an oral drug candidate undergoing Phase I clinical trials aimed at treating patients with metastatic castration-resistant prostate cancer. ESSA's approach targets the N-terminal domain of the androgen receptor, a critical component for the growth and survival of most prostate cancer cells. By selectively blocking this domain, ESSA aims to advance the next generation of hormone therapies for patients battling advanced prostate cancer.

Preventice Solutions, Inc. specializes in mobile cardiac health solutions and digital healthcare software aimed at improving patient management. Founded in 2007 and headquartered in Eagan, Minnesota, with additional offices in Fargo, North Dakota, San Francisco, California, and Houston, Texas, the company offers a range of services and devices designed to facilitate real-time patient monitoring. Its PatientCare Portal allows healthcare providers to independently manage and interpret patient data through a self-managed cloud-based platform. Additionally, the PatientView and PatientFlow Portals serve healthcare organizations and monitoring centers, respectively. Preventice Solutions also provides innovative wearable devices, such as the BodyGuardian Heart, a compact monitor promoting patient mobility and data collection, and the BodyGuardian Verité, a dual-modality remote cardiac sensor. These solutions enable precise identification and management of cardiac issues, ultimately connecting patients, clinicians, and healthcare facilities for enhanced care.

Citrine Medicine is a rare disease-focused pharmaceutical firm.

Tranquis Therapeutics, Inc. is a biotechnology company focused on developing immuno-therapeutics for neurodegenerative and aging-related diseases. Established in 2016 and based in San Mateo, California, the company is rooted in neuro-immunology research from Stanford University. Its lead candidate, TQS-168, targets myeloid immune cell dysfunction associated with various nervous system disorders. The therapeutic aims to address conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease, and age-related cognitive impairment. Tranquis Therapeutics is dedicated to advancing innovative treatments that could significantly alleviate the burden of these illnesses on patients and society. The company plans to initiate development for orphan diseases like ALS and FTD before expanding to more prevalent conditions such as Parkinson's and Alzheimer's disease.

Bolt Biotherapeutics, Inc. is a biotechnology company focused on developing innovative immunotherapy solutions for cancer treatment. The company employs its proprietary Boltbody platform, which features immune-stimulating antibody conjugates (ISAC) that link tumor-targeting antibodies with powerful immune stimulants. This approach aims to activate the immune system against tumors, effectively transforming cold tumors into immunologically active ones. Bolt Biotherapeutics is advancing several candidates in its pipeline, including BDC-1001, a monotherapy targeting HER2-expressing solid tumors, and BDC-3042, among others. Founded in 2015 and headquartered in Redwood City, California, the company leverages its expertise in myeloid biology and cancer drug development to create targeted therapies that harness both innate and adaptive immune responses.

Mereo is based in London and was founded in March 2015 to fund and develop novel, innovative specialist focused products from large pharmaceutical or biotechnology companies. Pharmaceutical companies face increasingly difficult choices in the allocation of internal resources to their drug development programs. With significant P&L constraints and rich pipelines it has become increasingly difficult for many companies to fully fund and advance development all of their drug candidates, especially beyond Phase 2. Mereo has been formed to take advantage of the global pharmaceutical industry's drive for creative ways to progress their clinical development pipelines. Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals. Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies. Additional product opportunities are under evaluation. Mereo's focus is the development of innovative medicines that have the potential to significantly transform the lives of patients suffering from rare and other specialised conditions around the world. To do this, the Company depends on the combination of its team's expertise in selecting and acquiring product opportunities, creating value in the development pipeline and structuring creative transactions. Mereo's internal expertise is complemented by a unique partnership with a leading global CRO, ICON. Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. Mereo will rapidly progress each of the products through further value inflection points before partnering or divesting its products. The Company also has the option to directly commercialise products, for example in orphan disease indications.

Legend Biotech is a clinical-stage biopharmaceutical company focused on discovering and developing innovative cell therapies for oncology and other medical conditions. The company employs a variety of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell therapies and natural killer cell-based immunotherapy. Its leading product candidate, LCAR-B38M/JNJ-4528, is designed as a chimeric antigen receptor T cell therapy specifically for treating multiple myeloma. Legend Biotech primarily generates its revenue through licensing and collaboration agreements, with a significant portion coming from the United States.